BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17374741)

  • 1. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.
    Tallman MS; Dewald GW; Gandham S; Logan BR; Keating A; Lazarus HM; Litzow MR; Mehta J; Pedersen T; Pérez WS; Rowe JM; Wetzler M; Weisdorf DJ
    Blood; 2007 Jul; 110(1):409-17. PubMed ID: 17374741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
    Gupta V; Tallman MS; He W; Logan BR; Copelan E; Gale RP; Khoury HJ; Klumpp T; Koreth J; Lazarus HM; Marks DI; Martino R; Rizzieri DA; Rowe JM; Sabloff M; Waller EK; DiPersio JF; Bunjes DW; Weisdorf DJ
    Blood; 2010 Sep; 116(11):1839-48. PubMed ID: 20538804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
    Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
    Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
    Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
    Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission].
    Bondarenko SN; Semenova EV; Vavilov VN; Stancheva NV; Morozova EV; Alianskiĭ AL; Babenko EV; Osipova NÉ; Zubarovskaia LS; Afanas'ev BV
    Ter Arkh; 2013; 85(7):18-25. PubMed ID: 24137943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
    Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics.
    Park EG; Yi ES; Choi YB; Sung KW; Koo HH; Yoo KH
    Pediatr Transplant; 2019 Jun; 23(4):e13397. PubMed ID: 30955250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
    Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
    Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):67-75. PubMed ID: 17336256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Estey E; de Lima M; Tibes R; Pierce S; Kantarjian H; Champlin R; Giralt S
    Blood; 2007 Feb; 109(4):1395-400. PubMed ID: 17038533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research.
    Lazarus HM; Pérez WS; Klein JP; Kollman C; Bate-Boyle B; Bredeson CN; Gale RP; Geller RB; Keating A; Litzow MR; Marks DI; Miller CB; Douglas Rizzo J; Spitzer TR; Weisdorf DJ; Zhang MJ; Horowitz MM
    Br J Haematol; 2006 Mar; 132(6):755-69. PubMed ID: 16487177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience.
    Alloin AL; Leverger G; Dalle JH; Galambrun C; Bertrand Y; Baruchel A; Auvrignon A; Gandemer V; Ragu C; Loundou A; Bilhou-Nabera C; Lafage-Pochitaloff M; Dastugue N; Nelken B; Jubert C; Rialland F; Plat G; Pochon C; Vannier JP; Rohrlich PS; Kanold J; Lutz P; Sirvent A; Oudin C; Cuccuini W; Michel G
    Bone Marrow Transplant; 2017 Apr; 52(4):516-521. PubMed ID: 27941778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission.
    Cho BS; Kim JH; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Eur J Haematol; 2013 May; 90(5):365-74. PubMed ID: 23414524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
    Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.
    Yanada M; Matsuo K; Emi N; Naoe T
    Cancer; 2005 Apr; 103(8):1652-8. PubMed ID: 15742336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.